Jefferies cut its price target on BMY stock to $65. Nevertheless, the shares are up 0.2% at $53.50, and have pared their year-to-date deficit to 8.5%. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), …
Shares of Bristol-Myers Squibb Co. (BMY) fell more than 16 percent Friday after the company announced that its Opdivo drug failed a study that would have expanded its use to lung cancer patients. BMY stock dropped more than $12 a …
Bristol-Myers investors are paid a 2.45% dividend. Credit Suisse puts a $68 price target on the stock. The consensus target is much lower at $63.41. Shares closed trading Thursday at $60.23. Another top company in the health care …
Those worries largely evaporated, though, and BMS stock eventually went on to generate nice year-to-date gains. Now, however, worries are resurfacing. Bristol-Myers Squibb announced its third-quarter results before the market opened on …
Key highlights in the pharma sector include a complete response letter (“CRL”) from the FDA for Johnson & Johnson’s JNJ investigational rheumatoid arthritis (“RA”) treatment and FDA approval for Merck’s MRK and Bristol-Myers Squibb’s …
When Bristol-Myers reported back on August 5 that Opdivo did not meet its targets for treatment of advanced non-small cell lung cancer, the stock tanked 16 percent. Merck stock, on the other hand spiked 10.4 percent on the news as …
NEW YORK (CNN/Money) - Bristol-Myers Squibb is battered black and blue, and it just got punched in the gut again. But one industry watcher thinks the drugmaker can retrace its way back from a series of management missteps and effect …
The fall is all around us - this Sunday is the autumnal equinox and last Sunday spelled the end of Summers - yet stocks still stubbornly refuse to drop. S&P 500 Index (INDEXSP:.INX) shares advanced 1.98% and have now risen in nine of 10 …
In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex’s common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer. …
NEW DELHI: Biocon Ltd surged over 2 per cent in trade on Friday after the India's premier biotechnology company announced its partnership with Bristol-Myers Squibb Company. At 09:50 am, Biocon pared most of its early …